Methylmalonic acidemia (MMA) is a severe, and sometimes lethal, monogenic metabolic disorder in need of improved treatments. A number of new genomic therapies, which include canonical adeno-associated virus gene addition, genome editing, and systemic mRNA therapy, have shown great promise in murine models of MMA. Each approach has unique advantages and disadvantages for treating genetic disorders like MMA. This article reviews traditional viral gene therapy experiments that have provided enabling proof of concept studies in animal models, and newer approaches that may emerge as effective treatments for MMA and related disorders of organic acid metabolism.
Get full access to this article
View all access options for this article.
References
1.
ManoliI, SloanJL, VendittiCP. Isolated methylmalonic acidemia. In: AdamMP, ArdingerHH, PagonetRA, et al., eds. GeneReviews®. Seattle WA: University of Washington, 1993.
2.
ManoliI, SysolJR, LiL, et al.Targeting proximal tubule mitochondrial dysfunction attenuates the renal disease of methylmalonic acidemia. Proc Natl Acad Sci U S A, 2013; 110:13552–13557.
3.
Carrillo-CarrascoN, ChandlerRJ, ChandrasekaranS, et al.Liver-directed recombinant adeno-associated viral gene delivery rescues a lethal mouse model of methylmalonic acidemia and provides long-term phenotypic correction. Hum Gene Ther, 2010; 21:1147–1154.
4.
ChuTH, ChienYH, LinHY, et al.Methylmalonic acidemia/propionic acidemia—the biochemical presentation and comparing the outcome between liver transplantation versus non-liver transplantation groups. Orphanet J Rare Dis, 2019; 14:73.
5.
CritelliK, McKiernanP, VockleyJ, et al.Liver transplantation for propionic acidemia and methylmalonic acidemia: perioperative management and clinical outcomes. Liver Transpl, 2018; 24:1260–1270.
6.
NiemiAK, KimIK, KruegerCE, et al.Treatment of methylmalonic acidemia by liver or combined liver-kidney transplantation. J Pediatr, 2015; 166:1455–1461. e1451.
7.
AndrewsE, JansenR, CraneAM, et al.Expression of recombinant human methylmalonyl-CoA mutase: in primary mut fibroblasts and Saccharomyces cerevisiae. Biochem Med Metab Biol, 1993; 50:135–144.
8.
RosenbergSA, AebersoldP, CornettaK, et al.Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med, 1990; 323:570–578.
9.
ChandlerRJ, TsaiMS, DorkoK, et al.Adenoviral-mediated correction of methylmalonyl-CoA mutase deficiency in murine fibroblasts and human hepatocytes. BMC Med Genet, 2007; 8:24.
10.
ChangCC, HsiaoKJ, LeeYM, et al.Towards metabolic sink therapy for mut methylmalonic acidaemia: correction of methylmalonyl-CoA mutase deficiency in T lymphocytes from a mut methylmalonic acidaemia child by retroviral-mediated gene transfer. J Inherit Metab Dis, 1999; 22:773–787.
11.
RinconA, AguadoC, DesviatLR, et al.Propionic and methylmalonic acidemia: antisense therapeutics for intronic variations causing aberrantly spliced messenger RNA. Am J Hum Genet, 2007; 81:1262–1270.
12.
ChandlerRJ, SloanJ, FuH, et al.Metabolic phenotype of methylmalonic acidemia in mice and humans: the role of skeletal muscle. BMC Med Genet, 2007; 8:64.
13.
PetersH, NefedovM, SarseroJ, et al.A knock-out mouse model for methylmalonic aciduria resulting in neonatal lethality. J Biol Chem, 2003; 278:52909–52913.
14.
ChandlerRJ, ZerfasPM, ShanskeS, et al.Mitochondrial dysfunction in mut methylmalonic acidemia. FASEB J, 2009; 23:1252–1261.
15.
ManoliI, SysolJR, EppingMW, et al.FGF21 underlies a hormetic response to metabolic stress in methylmalonic acidemia. JCI Insight, 2018; 3:1–16.
16.
WilnaiY, EnnsGM, NiemiAK, et al.Abnormal hepatocellular mitochondria in methylmalonic acidemia. Ultrastruct Pathol, 2014; 38:309–314.
17.
MurphyGE, LowekampBC, ZerfasPM, et al.Ion-abrasion scanning electron microscopy reveals distorted liver mitochondrial morphology in murine methylmalonic acidemia. J Struct Biol, 2010; 171:125–132.
18.
ZsengellerZK, AljinovicN, TeotLA, et al.Methylmalonic acidemia: a megamitochondrial disorder affecting the kidney. Pediatr Nephrol, 2014; 29:2139–2146.
19.
AnD, SchnellerJL, FrassettoA, et al.Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep, 2017; 21:3548–3558.
20.
KeuperM, HaringHU, StaigerH.Circulating FGF21 levels in human health and metabolic disease. Exp Clin Endocrinol Diabetes, 2019. May 20 [Epub ahead of print]; DOI: 10.1055/a-0879-2968.
21.
Gomez-SamanoMA, Grajales-GomezM, Zuarth-VazquezJM, et al.Fibroblast growth factor 21 and its novel association with oxidative stress. Redox Biol, 2017; 11:335–341.
22.
FisherFM, Maratos-FlierE. Understanding the physiology of FGF21. Annu Rev Physiol, 2016; 78:223–241.
23.
PetersHL, PittJJ, WoodLR, et al.Mouse models for methylmalonic aciduria. PLoS One, 2012; 7:e40609.
24.
ChandlerRJ, VendittiCP. Adenovirus-mediated gene delivery rescues a neonatal lethal murine model of mut(0) methylmalonic acidemia. Hum Gene Ther, 2008; 19:53–60.
25.
HarmonAW, ByrnesAP. Adenovirus vector toxicity. In: Brunetti-PierriN, ed. Safety and Efficacy of Gene-Based Therapeutics for Inherited Disorders. Cham: Springer, 2017.
ChandlerRJ, VendittiCP. Long-term rescue of a lethal murine model of methylmalonic acidemia using adeno-associated viral gene therapy. Mol Ther, 2010; 18:11–16.
28.
ZincarelliC, SoltysS, RengoG, et al.Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol Ther, 2008; 16:1073–1080.
29.
SenacJS, ChandlerRJ, SysolJR, et al.Gene therapy in a murine model of methylmalonic acidemia using rAAV9-mediated gene delivery. Gene Ther, 2012; 19:385–391.
30.
CunninghamSC, DaneAP, SpinoulasA, et al.Gene delivery to the juvenile mouse liver using AAV2/8 vectors. Mol Ther, 2008; 16:1081–1088.
31.
ChandlerRJ, VendittiCP. Pre-clinical efficacy and dosing of an AAV8 vector expressing human methylmalonyl-CoA mutase in a murine model of methylmalonic acidemia (MMA). Mol Genet Metab, 2012; 107:617–619.
32.
ChandlerRJ, LaFaveMC, VarshneyGK, et al.Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest, 2015; 125:870–880.
33.
DonsanteA, MillerDG, LiY, et al.AAV vector integration sites in mouse hepatocellular carcinoma. Science, 2007; 317:477.
34.
ChandlerRJ, SandsMS, VendittiCP. Recombinant adeno-associated viral integration and genotoxicity: insights from animal models. Hum Gene Ther, 2017; 28:314–322.
35.
ChandlerRJ, LaFaveMC, VarshneyGK, et al.Genotoxicity in mice following AAV gene delivery: a safety concern for human gene therapy?. Mol Ther, 2016; 24:198–201.
36.
LiC, YuS, ZhongX, et al.Transcriptome comparison between fetal and adult mouse livers: implications for circadian clock mechanisms. PLoS One, 2012; 7:e31292.
37.
HarringtonEA, SloanJL, ManoliI, et al.Neutralizing antibodies against adeno-associated viral capsids in patients with mut methylmalonic acidemia. Hum Gene Ther, 2016; 27:345–353.
38.
WongES, McIntyreC, PetersHL, et al.Correction of methylmalonic aciduria in vivo using a codon-optimized lentiviral vector. Hum Gene Ther, 2014; 25:529–538.
39.
SchnellerJL, LeeCM, LiA, et al.In vivo genome editing to treat methylmalonic acidemia (MMA) caused by methylmalonyl-CoA mutase deficiency (hMUT), presented at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy, Washington, DC. Mol Ther, 2019; 27:369.
40.
LiL, ChandlerRJ, LeungSS, et al.The combination therapy of ImmTOR™ with AAV Anc80 is therapeutic, safe, and repeatable in mice with methylmalonic acidemia, and compatible with the low seroprevalence of Anc80 Nabs in the patient population, presented at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy, Washington, DC. Mol Ther, 2019; 27:202.
41.
IlyinskiiPO, RoyC, MichaudA, et al.ImmTOR™ tolerogenic nanoparticles enhance transgene expression after both initial and repeat dosing in a mouse model of methylmalonic acidemia treated with an Anc80 AAV vector, presented at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy, Washington, DC. Mol Ther, 2019; 27:14–15.
42.
Di PasqualeG, ChandlerRJ, ChoiE, et al.AAV44. 9 and Clade E/F intermediate virus has unique glycan binding and transduction activity, presented at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy, Washington, DC. Mol Ther, 2019; 27:222.
43.
DeRosaF, SmithL, AskewK, et al.Treatment of metabolic disorders using lipid nanoparticle (LNP)-encapsulated messenger RNA therapeutics (MRT), presented at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy, Washington, DC. Mol Ther, 2019; 27:15–16.
44.
LiL, ChandlerRJ, Andres-MateosE, et al.Anc80 and AAV8 vectors mediate equivalent long-term hepatic correction of methylmalonyl-CoA mutase deficiency in a murine model of methymalonic acidemia (MMA), presented at the 21st Annual Meeting of the American Society of Gene and Cell Therapy, Chicago, IL. Mol Ther, 2018; 26:450.
45.
ZinnE, PacouretS, KhaychukV, et al.In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector. Cell Rep, 2015; 12:1056–1068.
46.
MaldonadoRA, LaMotheRA, FerrariJD, et al.Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci U S A, 2015; 112:E156–E165.
47.
MelianiA, BoisgeraultF, HardetR, et al.Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat Commun, 2018; 9:4098.
48.
PorroF, BortolussiG, BarzelA, et al.Promoterless gene targeting without nucleases rescues lethality of a Crigler-Najjar syndrome mouse model. EMBO Mol Med, 2017; 9:1346–1355.
49.
BorelF, TangQ, GernouxG, et al.Survival advantage of both human hepatocyte xenografts and genome-edited hepatocytes for treatment of alpha-1 antitrypsin deficiency. Mol Ther, 2017; 25:2477–2489.
50.
NygaardS, BarzelA, HaftA, et al.A universal system to select gene-modified hepatocytes in vivo. Sci Transl Med, 2016; 8:342ra379.
51.
BarzelA, PaulkNK, ShiY, et al.Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature, 2015; 517:360–364.
52.
ChandlerRJ, ChauN, ChiangK, et al.Targeted integration of MUT into the albumin locus using a promoterless AAV vector (Generide™) confers a hepatocellular growth advantage in mice with methylmalonic acidemia, presented at the 21st Annual Meeting of the American Society of Gene and Cell Therapy, Chicago, IL. Mol Ther, 2018; 26:446–447.
